Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Product sales, net	$ 2,108,233	$ 1,246,110	$ 7,458,678	$ 3,225,170
Cost of products sold	747,997	409,621	2,926,794	1,024,947
Gross profit	1,360,236	836,489	4,531,884	2,200,223
Selling, general and administrative expenses	2,968,625	2,275,274	9,729,594	8,146,498
Research and development expenses	356,179	21,438	588,043	237,089
Depreciation and amortization expense	16,353	16,505	52,113	74,861
Total operating expenses	3,341,157	2,313,217	10,369,750	8,458,448
Loss from operations	(1,980,921)	(1,476,728)	(5,837,866)	(6,258,225)
Interest expense	(4,608)	(569)	(11,604)	(8,727)
Gain on debt extinguishment-PPP	0	0	276,180	0
Loss before provision for income taxes and net of equity investments	(1,985,529)	(1,477,297)	(5,573,290)	(6,266,952)
Provision for income taxes	0	(24,717)	(333)	(26,217)
Loss before equity in net earnings (losses) of equity investments	(1,985,529)	(1,502,014)	(5,573,623)	(6,293,169)
Loss from China Joint Venture	(69,905)	0	(164,461)	0
Net loss	(2,055,434)	(1,502,014)	(5,738,084)	(6,293,169)
Net loss attributable to noncontrolling interests	(12,227)	(11,025)	(41,540)	(35,501)
Net loss attributable to Milestone Scientific Inc.	$ (2,043,207)	$ (1,490,989)	$ (5,696,544)	$ (6,257,668)
Net loss per share applicable to common stockholders—
Basic (in dollars per share)	$ (0.03)	$ (0.02)	$ (0.08)	$ (0.11)
Diluted (in dollars per share)	$ (0.03)	$ (0.02)	$ (0.08)	$ (0.11)
Weighted average shares outstanding and to be issued—
Basic (in shares)	69,573,795	65,817,132	68,609,143	56,478,151
Diluted (in shares)	69,573,795	65,817,132	68,609,143	56,478,151